Preliminary study to characterize differences in potential immunomodulatory effects of cyclosporine A using BALB/c and ICR mouse splenocytes

cyclosporine a (csa) is widely used as an immunosuppressant for the treatment of autoimmune diseases and immune regulation in transplant patients. due to its wide applicability, studies of unwanted side effects of csa are imperative. it has been found that not all patients treated with csa display the same types/patterns of adverse effects. to ascertain the bases for these differential responses, potential differing effects of csa on b-lymphocytes were analyzed. this entailed an assessment of changes in csa viability and mitotic activity within splenocyte populations from balb/c and icr mice. these particular strains were examined because: (1) in each of them, previously have been shown that differed in the respond to biological response modifiers, such as bacterial agents, and/or immunogens; (2) our own earlier studies showing strain-associated differences in ex vivo splenocyte/lymphocyte responses to other drug; and, (3) a potential immunomodulatory effect of any agent should be studied in at least two different strains during a broad toxicological evaluation. splenocytes from each strain were treated with 200 μg/ml csa, and cd4+, cd8+, and cd19+ cell viabilities were monitored at various time points during the exposure period. in general, there appeared to be a trend toward greater decreases in viability among balb/c b-lymphocytes than their icr counterparts as incubation progressed. differences related with t-lymphocyte sensitivity to drug associated to strains was not observed, because it was uniformly lethal throughout. with regard to mitotic activity, cells from icr mice were more susceptible to inhibition of spontaneous cell division at low concentrations of csa (relative to the rates of blastogenesis by balb/c counterparts). at higher concentrations of the drug however, there were no differences in the sensitivity of each strain. this work provides new insight into the mechanism of action of csa and illustrates the need for at least two different strains of